The Regulatory Role of microRNAs in the Therapeutic Response to Statins: Narrative Review
https://doi.org/10.52667/2712-9179-2026-6-1-3-14
Abstract
Statins or 3-hydroxy-3-methylglutaryl coenzyme A inhibitors are a class of cholester-ol-lowering drugs that are widely used in clinical practice for primary and secondary prevention of cardiovascular and cerebrovascular diseases associated with atherosclerosis. In recent years, there has been an increase in scientific and clinical interest in studying the relationship between statins and non-regulating ribonucleic acids circulating in the systemic bloodstream, known as circulating microRNAs. On the one hand, microRNAs play a crucial role in regulating the ex-pression of genes associated with the therapeutic response to statins, including the expression of key isoenzymes of statin metabolism in the liver, as well as directly and indirectly regulate the metabolism of high-density lipoproteins (HDL), low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL). On the other hand, statins can affect the expression levels of specific microRNAs circulating in the systemic bloodstream and affecting the epigenetic mecha-nisms regulating the expression of genes encoding key pathways of atherogenesis. This narrative review provides an update on the understanding of microRNAs' role as epigenetic regulators of interindividual differences in the therapeutic response to statins, as well as their potential as next-generation lipid-lowering medications in the long run. The influence of statins on altering the expression of microRNAs involved in various mechanisms of atherogenesis is also high-lighted.
About the Authors
Olga V. Marilovtceva
Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Krasnoyarsk 660022
Roman V. Khomchenkov
Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Krasnoyarsk 660022
Marina M. Petrova
Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Krasnoyarsk 660022
References
1. Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pr. 2012; 18: 1–78. https://doi.org/10.4158/EP.18.S1.1
2. Kucher A.N., Nazarenko M.S. The role of microRNA in atherogenesis. Kardiologiia. 2017; 57(9): 65–76. (In Russian)
3. Mancini G.B., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016) Can. J. Cardiol. 2016; 32: 35–65. https://doi.org/10.1016/j.cjca.2016.01.003
4. Santovito D., Egea V., Weber C. Small but smart: MicroRNAs orchestrate atherosclerosis development and progression. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2075-2086. https://doi.org/10.1016/j.bbalip.2015.12.013
5. Aryal B., Singh A.K., Rotllan N., et al. MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017;28(3):273-280. https://doi.org/10.1097/MOL.0000000000000420,
6. Keshavarz R., Reiner Ž., Zengin G., et al. MicroRNA-mediated regulation of LDL receptor: Biological and pharmacological implications. Curr Med Chem. 2024; 31(14): 1830-1838. https://doi.org/10.2174/0929867330666230407091652
7. Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21(11): 1290-1297. https://doi.org/10.1038/nm.3980
8. Balasubramanian R., Maideen N.M.P. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters - An overview. Curr Drug Metab. 2021; 22(5): 328-341. https://doi.org/10.2174/1389200222666210114122729
9. Xiang Q., Chen S.-Q., Ma L.-Y., et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myo-pathy: A meta-analysis. Pharm. J. 2018; 18: 721–729. https://doi.org/10.1038/s41397-018-0054-0
10. Ramsey L.B., Johnson S.G., E Caudle K., et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 2014; 96: 423–428. https://doi.org/10.1038/clpt.2014.125
11. Torres-Paz Y.E., Gamboa R., Fuentevilla-Álvarez G., et al. Involvement of expression of miR33-5p and ABCA1 in human peripheral blood mononuclear cells in coronary artery disease. Int J Mol Sci. 2024; 25(16): 8605. https://doi.org/10.3390/ijms25168605
12. El Saadany T., van Rosmalen B., Gai Z., et al. microRNA-206 modulates the hepatic expression of the organic ani-on-transporting polypeptide 1B1. Liver Int. 2019; 39(12): 2350-2359. https://doi.org/10.1111/liv.14212.
13. Xu Y., Hu J., Zhang Y., et al. LncRNA HOTAIR modulates the expression of OATP1B1 in HepG2 cells by sponging miR-206/miR-613. Xenobiotica. 2020; 50(12): 1494-1500. https://doi.org/10.1080/00498254.2020.1777484
14. Peng J.F., Liu L., Guo C.X., et al. Role of miR-511 in the regulation of OATP1B1 expression by free fatty acid. Biomol Ther (Seoul). 2015; 23(5): 400-406. https://doi.org/10.4062/biomolther.2015.010
15. Krattinger R., Boström A., Schiöth H.B., et al. microRNA-192 suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol. 2016; 310(11): G1044-51. https://doi.org/10.1152/ajpgi.00297.2015
16. Barbier R.H., McCrea E.M., Lee K.Y., et al. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Sci Rep. 2021; 11(1): 10765. https://doi.org/10.1038/s41598-021-90143-4
17. Amponsah P.S., Fan P., Bauer N., et al. microRNA-210 overexpression inhibits tumor growth and potentially reverses gem-citabine resistance in pancreatic cancer. Cancer Lett. 2017;388:107-117. https://doi.org/10.1016/j.canlet.2016.11.035.
18. Cao Y.X., Wen F., Luo Z.Y., et al. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line. J Cell Biochem. 2020; 121(10): 4022-4033. https://doi.org/10.1002/jcb.29541
19. https://go.drugbank.com
20. https://www.clinpgx.org/pathway
21. Rocha K.C., Pereira B.M.V., Rodrigues A.C. An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(6): 613–624. https://doi.org/10.1080/17425255.2018.1482276
22. Zhang F., Lei X., Yang X. Emerging roles of ncRNAs regulating ABCC1 on chemotherapy resistance of cancer - a review. J Chemother. 2024; 36(1): 1-10. https://doi.org/10.1080/1120009X.2023.2247202.
23. Sun J., Zhang H., Li L., et al. [Retracted] MicroRNA‑9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. Oncol Rep. 2023; 50(2): 153. https://doi.org/10.3892/or.2023.8590.
24. Chang C., Wang J., Wang H., Li J. Circ-ABCC1 enhances radioresistance of breast cancer cells via miR-627-5p/ABCC1 axis. Cell Mol Biol (Noisy-le-grand). 2022; 68(10): 187-192. https://doi.org/10.14715/cmb/2022.68.10.29.
25. Yahya S.M.M., Nabih H.K., Elsayed G.H., et al. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene. Breast Cancer Res Treat. 2024;204(1):133-149. https://doi.org/10.1007/s10549-023-07170-0.
26. Li Y., Liu Y., Ren J., et al. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol. 2018;138(3):499-508. https://doi.org/10.1007/s11060-018-2835-3.
27. Maslub M.G., Radwan M.A., Daud N.A.A., et al. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. Eur J Med Res 2023; 28: 381 (). https://doi.org/10.1186/s40001-023-01038-1
28. Balasubramanian R., Maideen N.M.P. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters - An overview. Curr Drug Metab. 2021; 22(5): 328-341. https://doi.org/10.2174/1389200222666210114122729
29. Yee J, Kim H, Heo Y, Yoon HY, Song G, Gwak HS. Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis. J Pers Med. 2021; 11(7): 677. https://doi.org/10.3390/jpm11070677
30. Nakano M., Nakajima M. Current knowledge of microRNA-mediated regulation of drug metabolism in humans. Exp Opin Drug Metab Toxicol. 2018; 14(5): 493–504. https://doi.org/10.1080/17425255.2018.1472237
31. Lodato N.J., Melia T., Rampersaud A., Waxman DJ. Sex-differential responses of tumor promotion-associated genes and dysregulation of novel long noncoding RNAs in constitutive androstane receptor-activated mouse liver. Toxicol Sci. 2017; 159(1): 25–41. https://doi.org/10.1093/toxsci/kfx114
32. Li D., Tolleson W.H., Yu D., et al. Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2019; 37(3): 180-214. https://doi.org/10.1080/10590501.2019.
33. Lolodi O., Wang Y.M., Wright W.C., Chen T. Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017; 18(12): 1095-1105. https://doi.org/10.2174/1389200218666170531112038.
34. Zhang S.Y., Surapureddi S., Coulter S., et al. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012; 82(3): 529-540. https://doi.org/10.1124/mol.112.078386.
35. Tantawy M., Collins J.M., Wang D. Genome-wide microRNA profiles identify miR-107 as a top miRNA associating with expression of the CYP3As and other drug metabolizing cytochrome P450 enzymes in the liver. Front. Pharmacol. 2022; 13: 943538. https://doi.org/10.3389/fphar.2022.943538
36. Baldán Á., de Aguiar Vallim T.Q. miRNAs and High-Density Lipoprotein metabolism. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2053-2061. https://doi.org/10.1016/j.bbalip.2016.01.021,
37. Jeon T.I., Osborne T.F. miRNA and cholesterol homeostasis. Biochim Biophys Acta. 2016; 1861 (12 Pt B): 2041-2046. https://doi.org/10.1016/j.bbalip.2016.01.005
38. Andreou I., Sun X., Stone P.H., et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307-318. https://doi.org/10.1016/j.molmed.2015.02.003
39. Fernández-Tussy P., Ruz-Maldonado I., Fernández-Hernando C. MicroRNAs and circular RNAs in lipoprotein metabolism. Curr Atheroscler Rep. 2021; 23(7): 33. https://doi.org/10.1007/s11883-021-00934-3
40. Aryal B., Singh A.K., Rotllan N., et al. MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017; 28(3): 273-280. https://doi.org/10.1097/MOL.0000000000000420,
41. Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21(11): 1290-1297. https://doi.org/10.1038/nm.3980,
42. Keshavarz R., Reiner Ž., Zengin G., et al. MicroRNA-mediated regulation of LDL receptor: Biological and pharmacological implications. Curr Med Chem. 2024; 31(14): 1830-1838. https://doi.org/10.2174/0929867330666230407091652
43. Zambrano T., Hirata R.D.C., Hirata M.H., et al. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci. 2018; 117: 55-61. https://doi.org/10.1016/j.ejps.2018.02.007
44. Cerda A., Bortolin R.H., Manriquez V., et al. Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells. Pharmacol Rep. 2021; 73(3): 868-880. https://doi.org/10.1007/s43440-021-00241-3
45. Feinberg M.W., Moore K.J. MicroRNA regulation of atherosclerosis. Circ Res. 2016; 118(4): 703-720. https://doi.org/10.1161/CIRCRESAHA.115.306300
46. Chen H.L., Lo C.H., Huang C.C., et al. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis. J Clin Invest. 2021; 131(1): e130740. https://doi.org/10.1172/JCI130740,
47. Wang F., Ma H., Liang W.J., et al. Lovastatin upregulates mi-croRNA-29b to reduce oxidative stress in rats with multiple car-diovascular risk factors. Oncotarget. 2017; 8(6): 9021-9034. https://doi.org/10.18632/oncotarget.14462.,
48. Yu F., Lv X.S., Jiang A.Y., et al. Pitavastatin ameliorates myocar-dial injury by inhibiting myocar-dial inflammation and ox-idative stress by modulating the mi-croRNA-106B-5p/mitogen-activated protein kinase kinase kinase 2 axis. J Physiol Phar-macol. 2024; 75(3). https://doi.org/10.26402/jpp.2024.3.03,
49. Jia M., Li Q., Guo J., et al. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022; 130(7): 1038-1055. https://doi.org/10.1161/CIRCRESAHA.121.319540
50. Lin H.J., Yu S.L., Su T.C., et al. Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia. Biosci Rep. 2020; 40(9): BSR20201885. doi:10.1042/BSR20201885
51. Sodi R., Eastwood J., Caslake M., et al. Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clin Chim Acta. 2017; 466: 13-19. https://doi.org/10.1016/j.cca.2016.12.031
52. Ubilla C.G., Prado Y., Angulo J., et al. MicroRNA-33b is a potential non-Invasive biomarker for response to atorvastatin treatment in Chilean subjects with hypercholesterolemia: A pilot study. Front Pharmacol. 2021; 12: 674252 https://doi.org/10.3389/fphar.2021.674252,
53. Saavedra K., Leal K., Saavedra N., et al. MicroRNA-20a-5p Downregulation by atorvastatin: A potential mechanism involved in lipid-lowering therapy. Int J Mol Sci. 2022; 23(9): 5022. https://doi.org/10.3390/ijms23095022
54. Mulchandani R., Lyngdoh T., Kakkar A.K. Statin use and safety concerns: an overview of the past, present, and the future. Expert Opin. Drug Saf. 2020; 19: 1011–1024. https://doi.org/10.1080/14740338.2020.1796966
55. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297. https://doi.org/10.1016/s0092-8674(04)00045-5
56. Zhou L., Lim M.Y.T., Kaur P., et al. Importance of miRNA stability and alternative primary miRNA isoforms in gene regu-lation during Drosophila development. Elife. 2018; 7 https://doi.org/10.7554/eLife.38389.,
57. Hartig S.M., Hamilton M.P., Bader D.A., McGuire S.E. The miRNA interactome in metabolic homeostasis. Trends Endocrinol. Metab. 2015; 26: 733–745. https://doi.org/10.1016/j.tem.2015.09.006
58. Li C., Tian J., Liu N., et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. J Lipid Res. 2024; 65(7): 100576. https://doi.org/10.1016/j.jlr.2024.100576.
59. Lv Y.C., Yang J., Yao F., et al. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregula-tion of ATP-binding cassette trans-porter A1. Atherosclerosis. 2015; 240(1): 80-89. https://doi.org/10.1016/j.atherosclerosis.2015.02.044
60. Alvarez M.L., Khosroheidari M., Eddy E., Done S.C. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015; 242(2): 595-604. https://doi.org/10.1016/j.atherosclerosis.2015.08.023
61. Goedeke L., Rotllan N., Ramírez C.M., et al. miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. Atherosclerosis. 2015; 243(2): 499-509. https://doi.org/10.1016/j.atherosclerosis.2015.09.033
62. Ru P., Guo D. microRNA-29 mediates a novel negative feedback loop to regulate SCAP/SREBP-1 and lipid metabolism. RNA Dis. 2017; 4(1): e1525. https://doi.org/10.14800/rd.1525
63. Sidorkiewicz M. Is microRNA-33 an appropriate target in the treatment of atherosclerosis?. Nutrients. 2023; 15(4): 902 https://doi.org/10.3390/nu15040902
64. Huang K., Pokhrel A., Echesabal-Chen J., et al. Inhibiting miR-33a-3p expression fails to enhance ApoAI-mediated choles-terol efflux in pro-inflammatory endothelial cells. Medicina (Kaunas). 2025; 61(2): 329. https://doi.org/10.3390/medicina61020329
65. Wang J., Hu X., Hu X., et al. MicroRNA-520c-3p targeting of RelA/p65 suppresses atherosclerotic plaque formation. Int J Biochem Cell Biol. 2021; 131: 105873. https://doi.org/10.1016/j.biocel.2020.105873
66. Chen X., Liu Y., Zhou Q., et al. MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes. Front Genet. 2024; 15: 1469094. https://doi.org/10.3389/fgene.2024.1469094
67. Xu Y., Gao J., Gong Y., et al. Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. Atherosclerosis. 2020; 297: 111-119. https://doi.org/10.1016/j.atherosclerosis.2020.02.004
68. Goedeke L., Rotllan N., Canfrán-Duque A., et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015; 21(11): 1280-1289. https://doi.org/10.1038/nm.3949
69. Wang Y., Li F., Gao X., et al. miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9. J Endocrinol. 2024; 262(3): e230402. https://doi.org/10.1530/JOE-23-0402
70. Jiang H., Zhang J., Du Y., et al. microRNA-185 modulates low density lipoprotein receptor expression as a key posttran-scriptional regulator. Atherosclerosis. 2015; 243(2): 523-532. https://doi.org/10.1016/j.atherosclerosis.2015.10.026
71. Li C., Tian J., Liu N., et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. J Lipid Res. 2024; 65(7): 100576. https://doi.org/10.1016/j.jlr.2024.100576
72. Liu N., Tian J., Steer C.J., et al. MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux. Hepatology. 2025; 81(1): 111-125. https://doi.org/10.1097/HEP.0000000000000672
73. Lu X., Yang B., Yang H., et al. MicroRNA-320b modulates cholesterol efflux and atherosclerosis. J Atheroscler Thromb. 2022; 29(2): 200-220. https://doi.org/10.5551/jat.57125
74. Xu X., Dong Y., Ma N., et al. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice. Me-tabolism. 2021; 119: 154768. https://doi.org/10.1016/j.metabol.2021.154768
75. Dong J., He M., Li J., et al. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight. 2020; 5(23): e143812. https://doi.org/10.1172/jci.insight.143812
76. Tanashyan M.M., Shabalina A.A., Kuznetsova P.I., Raskurazhev A.A. miR-33a and its association with lipid profile in pa-tients with carotid atherosclerosis. Int J Mol Sci. 2023; 24(7): 6376. https://doi.org/10.3390/ijms24076376
77. Barut Z., Akdeniz F.T., Avsar O., Cabbar A.T. Investigation of miRNA-199a-5p expression and its clinical association with LDL Cholesterol levels in atherosclerosis. In Vivo. 2024; 38(6): 2656-2664. https://doi.org/10.21873/invivo.13742]
78. Petrova М.М., Shnayder N.A., Dmitrenko D.V., et al. The pattern of circulating micrornas in acute myocardial infarction. Transbaikalian Medical Bulletin. 2025;(2):140-151. (In Russian) https://doi.org/10.52485/19986173_2025_2_140
79. Petrova M.M., Shnayder N.A., Petrov A.V., et al. MicroRNA-134-5p and the heart-brain axis. Siberian Medical Review. 2024;(6):14-18. https://doi.org/10.20333/25000136-2024-6-14-18
80. Laffont B., Rayner K.J. MicroRNAs in the pathobiology and therapy of atherosclerosis. Can J Cardiol. 2017; 33(3): 313-324. https://doi.org/10.1016/j.cjca.2017.01.001
81. Goedeke L., Wagschal A., Fernández-Hernando C., Näär A.M. miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2047-2052. https://doi.org/10.1016/j.bbalip.2016.03.007
82. Zaidi S.A., Fan Z., Chauhdari T., Ding Y. MicroRNA regulatory dynamic, emerging diagnostic and therapeutic frontier in atherosclerosis. Microvasc Res. 2025; 160: 104818. https://doi.org/10.1016/j.mvr.2025.104818
83. Andreou I., Sun X., Stone P.H., et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307-318. https://doi.org/10.1016/j.molmed.2015.02.003
84. Ganjali S., Aghaee-Bakhtiari S.H., Reiner Ž., Sahebkar A. Differential expression of miRNA-223 in coronary in-stent reste-nosis. J Clin Med. 2022; 11(3): 849. https://doi.org/10.3390/jcm11030849
85. Khan A.A., Gupta V., Mahapatra N.R. Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic dis-eases and development of novel therapeutics. Drug Discov Today. 2022; 27(8): 2170-2180. https://doi.org/10.1016/j.drudis.2022.05.003
86. Della Corte V., Todaro F., Cataldi M., Tuttolomondo A. Atherosclerosis and its related laboratory biomarkers. Int J Mol Sci. 2023; 24(21): 15546. https://doi.org/10.3390/ijms242115546
87. Gorabi A.M., Ghanbari M., Sathyapalan T., et al. Implications of microRNAs in the pathogenesis of atherosclerosis and prospects for therapy. Curr Drug Targets. 2021; 22(15): 1738-1749. https://doi.org/10.2174/1389450122666210120143450
88. Myocardial infarction and vascular cognitive disorders / Edited by M.M. Petrova, N.A. Shnayder. Saint Petersburg: DEAN Publishing House, 2025. 528 p. ISBN 978-5-6052545-0-8. eLIBRARY ID: 83153049 EDN: ZNZIJN (In Russian)
89. Shnayder N.A., Bader V.V., Nasyrova R.F. Prospects of pharmacotranscriptomics in understanding the effects of antiepileptic drugs and searching for new classes of antiepileptic drugs. Pharmacogenetics and Pharmacogenomics. 2025; 4: 10-17. (In Russian). https://doi.org/10.37489/2588-0527-2025-4-10-17
90. Shnayder N.A., Pekarets N.A., Pekarets N.I., et al. The role of microRNAs as regulators of systemic inflammatory response in anticonvulsant-induced metabolic syndrome. Epilepsy and Paroxysmal Conditions. 2025; 17 (2): 208–226. (In Russian). https://doi.org/10.17749/2077-8333/epi.par.con.2025.239
Review
For citations:
Marilovtceva O.V., Khomchenkov R.V., Petrova M.M. The Regulatory Role of microRNAs in the Therapeutic Response to Statins: Narrative Review. Personalized Psychiatry and Neurology. 2026;1(6):3-14. https://doi.org/10.52667/2712-9179-2026-6-1-3-14
Views:
151
JATS XML
Email this article 